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Purpose.This study aimed to evaluate the effect of chronic treatment with chaetomellic acid A (CAA) on oxidative stress and renal
function in amodel of renalmass reduction.Methods.MaleWistar ratswere subjected to 5/6 nephrectomy (RMR) or sham-operated
(SO). One week after surgery, rats have been divided into four experimental groups: RMR: RMR rats without treatment (𝑛 = 14);
RMR + CAA: RMR rats treated with CAA (𝑛 = 13); SO: SO rats without treatment (𝑛 = 13); and SO + CAA: SO rats treated
with CAA (𝑛 = 13). CAA was intraperitoneally administered in a dose of 0.23 𝜇g/Kg three times a week for six months. Results.
RMR was accompanied by a significant reduction in catalase and glutathione reductase (GR) activity (𝑝 < 0.05) and a decrease in
reduced glutathione (GSH)/oxidized glutathione (GSSG) ratio. CAA administration significantly increased catalase andGR activity
(𝑝 < 0.05) and increased GSH/GSSG ratio, but no significant difference between the treated and nontreated groups was found in
this ratio. No significant differences were found between the RMR groups in any of the parameters of renal function. However, CAA
administration slightly improves some parameters of renal function. Conclusions.These data suggest that CAA could attenuate 5/6
RMR-induced oxidative stress.
1. Introduction
Chronic kidney disease (CKD) is a global public health
problem associated with increased morbidity, mortality, and
health care cost [1]. The major goal for controlling devel-
opment of CKD is slowing progression to end-stage renal
disease. However, slowing its development still represents
a clinical challenge [2]. Consequently, the search for new
therapeutic modalities remains an issue of actual importance
and of interest both to researchers and clinicians.
CKD is characterized by a progressive loss of renal func-
tion, chronic inflammation, vascular remodeling, glomerular
and tubulointerstitial fibrosis, and oxidative stress [2]. Oxida-
tive stress is implicated in the pathogenesis of renal injury
being a constant feature of advanced renal disease and plays
a major role in progressive deterioration of renal function
and structure [3, 4].The precise mechanism of CKD-induced
oxidative stress has not been completely explained. Impaired
oxidative balance in CKD is likely to come from a combina-
tion of increased reactive oxygen species (ROS) production
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and reduced clearance as well as an ineffective antioxidant
defense mechanism [2, 5].The increase of ROS leads to tissue
injury and dysfunction by attacking, denaturing, and modi-
fying structural and functional molecules and by activating
redox-sensitive transcription factors and the signal trans-
duction pathway. These events, in turn, promote necrosis,
apoptosis, inflammation, fibrosis, and other disorders [5].
Farnesyl transferase (FTase) is a zinc enzyme that consists
of a 49 kDa 𝛼-subunit and a 46 kDa 𝛽-subunit [6]. Initial
interest in FTase arose from the discovery that farnesylation is
absolutely necessary for the activity of small GTPase protein
p21 Ras, Harvey-Ras (Ha-Ras), Neural-Ras (N-Ras), and
Kirsten-Ras (Ki-Ras4A and Ki-Ras4B) [7, 8]. Such proteins
have a pivotal role in the signal transduction that controls cell
growth and differentiation [9] and are involved in the regula-
tion of the intracellular redox state [10–12].However, different
Ras isoforms generate opposing effects on the redox state
of cells. Activated Ki-Ras isoform decreases ROS levels by
reducing superoxide levels via an activation of the mitochon-
drial antioxidant enzyme, Mn-superoxide dismutase [12],
while activated Ha-Ras isoform increases intracellular levels
of ROS via upregulation of the plasma membrane NADPH
oxidase that is responsible for the transfer of electrons to
molecular oxygen leading to the production of superoxide
anions [10, 12–14]. Ha-Ras oxidative stress-induced apoptosis
was reversed by farnesyl transferase inhibitors in human
umbilical vein endothelial cells [13]. So, one molecular target
for prevention oxidative injury associated with CKD may be
the Ha-Ras isoform.
Chaetomellic acids are a class of dicarboxylic acids that
were isolated from fermentation extract of the coelomycete
Chaetomella acutiseta. Chaetomellic acid A (CAA) has been
identified as potent and highly specific inhibitor of FTase
[15], which selectively blocks Ha-Ras farnesylation [16]. CAA
has shown to significantly decrease oxidative stress-induced
apoptosis in human renal proximal tubular cells and human
umbilical vein endothelial cells [17]. Furthermore, CAA
administration in rats, after brain damage induced by an
excitotoxic stimulus, increased intracellular concentration
of nonprenylated inactive Ha-Ras and significantly reduced
superoxide production [16]. Additionally, the administration
of farnesyl transferase inhibitors, including CAA, reduced
renal damage after unilateral ureteral obstruction (UUO) in
mice [18]. Ha-Ras proteins were detected in human kidney in
different kinds of cells [9]; thus it is reasonable to propose that
CAAmay protect the kidney from oxidative injury following
renal mass reduction.
Therefore, in this study we evaluated the effects of chronic
treatment with CAA on renal failure and oxidative stress in
rats with 5/6th renal mass reduction.
2. Materials and Methods
2.1. Animals. Sixty male Wistar rats (Rattus norvegicus)
(obtained from Harlan Interfauna Iberica, S.L.; Barcelona,
Spain) with initial body weights of 359 to 402 g were used in
this study. Animals were housed at the University of Tra´s-os-
Montes andAltoDouro facilities under controlled conditions
of temperature (23 ± 2∘C) and relative humidity (55 ± 5%)
on a light-dark cycle (12h : 12h) and provided with a standard
laboratory diet (Mucedola, Milan, Italy) and tap water ad
libitum. All animal procedures were done in accordance with
the EuropeanDirective 2010/63/EU and theNational Decree-
Law 113/2013 on the protection of animals used for scientific
purposes.
2.2. Surgical Procedure and Experimental Groups. After seven
weeks of acclimatization, animals were subjected to 5/6th
renal mass reduction (RMR) or sham-operated (SO). RMR
was performed as described previously [19]. Briefly, the
animals were anaesthetized by intraperitoneal injection with
ketamine (70mg/Kg; Imalgene 1000, Merial S.A.S., Lyon,
France) and xylazine (10mg/Kg; Rompun 2%, Bayer S.A.,
Kiel, Germany) and the right kidney was exposed by midline
laparotomy, the right renal artery, vein, and ureter were
ligated with 4/0 silk suture, and the entire kidney was
removed. Then, approximately two-thirds of the left kidney
was removed by excision of the upper and lower poles. The
weight of the removed renal tissue was measured. After
suture of the abdomen, animals were maintained in a warm
environment until recovery from anesthesia was complete
and then returned to their cages. SO animals underwent a
similar procedure. However, only manipulation of the renal
pedicles, without any renal mass removal, was performed
in these animals. The approximate weight of the remaining
renal tissue was calculated on the basis of the removed tissue,
assuming that the right and left kidneys had equal weights.
One week after surgical procedure, surviving animals
(𝑛 = 53) were divided into four experimental groups: RMR:
RMR rats without treatment (𝑛 = 14); RMR + CAA: RMR
rats treated with CAA (𝑛 = 13); SO: SO rats without
treatment (𝑛 = 13); and SO + CAA: SO rats treated with
CAA (𝑛 = 13). The rats with renal mass reduction were
distributed by the RMR groups according to the serum
creatinine concentrations and the weight of the removed
renal tissue to ensure equal reduction in renal mass. CAA
was intraperitoneally administered in a dose of 0.23𝜇g/Kg
per body weight three times a week for six months. Along
the experimental protocol animals were daily observed and
animals’ body weight was measured weekly during all the
experimental protocol. Mortality was also monitored.
2.3. Urine and Blood Parameters Measurements. Before and
every month after surgery, urine and blood samples were
collected. For urine parameters measurements each rat was
separately housed in a metabolic cage for two days to get
accustomed to isolation conditions, and urine was collected
during the following two days to measure volume, urine
specific gravity, creatinine concentration, and proteinuria.
Blood samples (150 𝜇l) were obtained from a cut in the
tail tip into heparinized capillaries. Haematocrit (Ht) was
determined in centrifuged capillaries (1500𝑔 for 15min) and
separated plasma served to measure creatinine, blood urea
nitrogen (BUN), phosphorus, and potassium concentrations
(Daytona Rx, Randox) [20]. Glomerular filtration rate was
estimated from the creatinine clearance, which was calcu-
lated by employing a standard formula [Uc × V/Pc, where
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Uc=urine creatinine (mg/dl),V =urine volume (ml/min/100 g
body weight), and Pc = plasma creatinine (mg/dl)].
2.4. Blood Pressure Measurement. On the day of sacrifice, the
blood pressure was measured. The animals were maintained
on surgical anesthesia throughout the entire measurement
study with isofluorane. Briefly, the right femoral artery was
exposed, and indwelling 24G catheters (Introcan Safety
G24, B/Braun) were inserted and fixed with 4/0 silk ligatures,
taking caution not to twist the vessels. Then, the femoral
artery was connected to a Datex-Ohmeda S/5 anesthesia
monitor (Datex-Ohmeda Division, Instrumentarium Corp.,
Helsinki, Finland) through heparin-filled tubes connected to
pressure transducers placed at the level of the heart on a
plastic support. After being stabilized for 5min, the values
of systolic blood pressure (SBP), diastolic blood pressure
(DBP), mean arterial pressure (MAP), and heart rate (HR)
were continuously monitored and recorded every 15 sec for
a period of 120 sec. At the end of the study the rats were
sacrificed using an overdose of anesthesia followed by exsan-
guination by cardiac puncture as indicated by the Federation
of European Laboratory Animal Science Associations [21].
The kidneys were removed and samples were immediately
frozen and stored at −80∘C until analysis.
2.5. Oxidative Stress Studies
2.5.1. Kidney Tissue Homogenate Preparation. The kidneys
were weighed and then minced with scissors and homog-
enized in ice-cold sodium phosphate buffer (KH2PO2)
100mM, pH 7.4. The homogenization was carried out in
a Potter-Elvejhem homogenizer type after first removing
the capsule to obtain 1 : 10 (w/v) dilution. A fraction of
the homogenate was stored at −20∘C until the evaluation
of lipid peroxidation by MDA method and evaluated lipid
hydroperoxides. The remaining fraction of the homogenate
was centrifuged at 1, 500𝑔 for 10min at 4∘C.The supernatant
was then centrifuged at 16, 000𝑔 for 20min at 4∘C and
used to determine total protein, catalase (CAT) activity,
glutathione reductase (GR) activity, and reduced glutathione
(GSH)/oxidized glutathione (GSSG) ratio.
2.5.2. Assessment of Antioxidant Status. TheCAT activity was
measured with a Clark-type oxygen electrode (Hansatech)
according to Del Rı´o et al. [22]. Assay was conducted as
described by Paula Santos et al. [23]. The reaction medium
consisted of potassium phosphate buffer (50mM KH2PO4
pH 7.4) and H2O2 (1M) in a final volume of 1ml. Medium
buffer was previously subjected to a nitrogen stream to
decrease the dissolved oxygen. After 2min of thermostatic
incubation at 25∘C and stabilization, H2O2 was added to
the reaction medium. Slope was measured and after 30 sec
the enzyme extract (diluted 100 times) was added and
new slope measured. CAT activity was calculated as mmol
H2O2/min/mg of protein.
TheGR activity was performed according to Paula Santos
et al. [23] and Smith et al. [24]. The reaction medium con-
sisted of potassium phosphate buffer (100mM KH2PO4 and
0.5mM EDTA, pH 7.4), 100mMGSSG, and 10mMNADPH.
GSSG was added after 2min of thermostatic incubation
at 25∘C to initiate the reaction. GR activity was measured
at 340 nm at 25∘C by NADPH oxidation. The result was
expressed as nmol NADPH oxidized/min/mg of protein.
Concentrations of GSH and GSSG were measured from
the supernatant fraction that was obtained in the previously
described enzyme assays after ultrasonication and centrifuga-
tion. The supernatant, kept at 0∘C, was used for the GSH and
GSSGassays on the sameday.This determinationwas done by
spectrofluorimetry, as previously described [25, 26]. Briefly,
GSH was measured by fluorescence using a Varian Eclipse
spectrofluorimeter with emission and excitation wavelengths
of 426 and 339 nm, respectively, after incubation of 50𝜇L
of supernatant with 1.95mL of 100mM K-phosphate buffer
(pH 8.0) plus 5mM EDTA and 200 𝜇L of the fluorescence
reagent, o-phthalaldehyde (OPT) (1mgmL−1), for 15min
in the dark and at room temperature (25∘C). For GSSG
assay, 125 𝜇L of the supernatant was incubated with 50𝜇L
of N-ethylmaleimide 40mM for 30min at room temper-
ature (25∘C). Thereafter, 140 𝜇L of mixture was incubated
with 1.66mL NaOH 100mM plus 200𝜇L OPT solution
(1mgmL−1) and incubated for 15min in the dark and at room
temperature (25∘C). Fluorescence was determined similarly
to that of the GSH assay. Concentrations of GSH and GSSG
in the samples were calculated against standard calibration
curves.
2.5.3. Assessment of Lipid Peroxidation. Lipid peroxidation
was evaluated as thiobarbituric acid reactive products, as
previously described by Eriksson et al. [27], and the determi-
nation of malondialdehyde (MDA) was based on the deriva-
tization with thiobarbituric acid [28]. The amount of MDA
formed was calculated using a molar extinction coefficient of
1.56 × 105M−1 cm−1 and expressed as nanomoles MDA per
milligram protein.
In order to quantify lipid hydroperoxides, the fer-
rous oxidation-xylenol orange (FOX) II assay was used;
50 𝜇L of the total lipid extract was added to 950 𝜇L
of the FOX reagent solution (100 𝜇M xylenol orange,
250 𝜇M Fe2+, 25mM H2SO4, and 4mM 2,6-di-tert-butyl-
p-hydroxytoluene (BHT) in 90% (v/v) methanol) in micro-
tubes, homogenized in a vortex mixer, and incubated for
30min at room temperature, in the dark. After incu-
bation, the absorbance of samples was read at 560 nm
against H2O2 standards with concentrations ranging from
0.0 to 0.4mM (H2O2 1mM, FOX2 reagent and water). The
FOX reagent (100mL) was prepared as follows: 250𝜇M
(NH4)2Fe(SO4)⋅6H2O (9.8mg) and 25mM H2SO4 (139 𝜇L)
were dissolved in 5mL of water, mixed with 4mM BHT
(88.2mg), 100𝜇M xylenol orange (7.2mg), and 45mL of
methanol. Then, other 45mL of methanol and 5mL of water
were added [26, 29].
2.5.4. Protein Concentration Measurement. The protein con-
tent was determined by the Biuretmethodwith bovine serum
albumin as standard [30]. All chemicals used in the enzymatic
activity were of analytical purity and were obtained from
Sigma Chemical Co. (Sigma Aldrich, San Diego, USA).
4 BioMed Research International
Table 1: Blood pressure and heart rate.
Group SBP DBP MAP HR
SO (𝑛 = 9) 148.22 ± 6.36 113.00 ± 3.42 128.89 ± 4.24 406.67 ± 5.77
SO + CAA (𝑛 = 10) 146.00 ± 5.32 111.90 ± 3.15 127.60 ± 3.84 407.00 ± 8.17
RMR (𝑛 = 9) 202.22 ± 9.61ab 140.56 ± 6.28ab 167.00 ± 7.54ab 420.00 ± 8.33
RMR + CAA (𝑛 = 7) 184.29 ± 9.79ab 133.71 ± 8.48b 155.14 ± 8.55ab 404.29 ± 13.78
aSignificant differences compared to SO (𝑝 < 0.05); bsignificant differences compared to SO + CAA (𝑝 < 0.05); SBP: systolic blood pressure; DBP: diastolic
blood pressure; MAP: mean arterial pressure; HR: heart rate.
2.6. Statistical Analysis. Statistical differences between
groups were evaluated by one-way analysis of variance
(ANOVA) for independent samples, followed by Tukey HSD
post hoc tests, when the data was normally distributed. In
the other cases the Kruskal-Wallis test was used, followed by
multiple comparisons by Dunn’s procedure.
For the analysis of the differences over time we used
the repeated measures ANOVA, followed by Tukey HSD
post hoc tests, when the data was normally distributed, and
Friedman’s ANOVA for related samples, followed by the
Dunn-Bonferroni test for the multiple comparisons, in the
other cases. Survival time was estimated using Kaplan-Meier
estimates from first day of treatment until death. The four
groups were compared using the Log-Rank, if there were an
overall difference between the groups; pair-wise comparisons
were made among all pairs.
The normality of the data was checked with the Shapiro-
Wilk test. All data are presented as mean ± standard error
and differences were considered statistically significant for
𝑝 < 0.05.
3. Results
3.1. Survival. No mortality was observed in the SO groups
throughout the six months of experimental period. Two
RMR untreated rats and five RMR animals treated with
CAA died during the experimental period (Figure 1). There
was a statistical significant difference in cumulative survival
between RMR + CAA group and the SO groups.
3.2. Blood Pressure and Heart Rate. As expected, SBP, DBP,
and MAP were significantly increased in the RMR groups
compared with SO groups. Although SBP, DBP, and MAP
were lower in the CAA-treated than in the untreated
RMR group, the differences were not statistically significant
(Table 1). No significant differences were found between the
different groups in heart rate (Table 1).
3.3. Body Weight and Haematocrit. Table 2 provides the
initial and follow-up body weights for all groups. The body
weight values of animals belonging to RMR and RMR +
CAA groups were similar during the experimental period,
and no significant differences were observed between these
groups. The haematocrit values of RMR and RMR + CAA
groups decreased mainly in the five and six months’ time
points and were significantly lower than in the SO groups.
At sixth month haematocrit value was higher in the RMR +
CAA group (46.1 ± 2.0) than in the RMR group (43.5 ± 1.7);
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Figure 1: Kaplan-Meier survival analysis. Note significantly reduced
survival for group RMR + CAA compared with SO groups (𝑝 =
0.015).
however this difference was not statistically significant
(Table 2).
3.4. Renal Function. The course of the different parameters
of renal function in all groups is summarized in Table 2. As
we can see, from two-month time point significantly higher
plasma levels of BUN and creatinine were observed in the
RMR groups compared with the SO groups. Proteinuria was
observed as early as one month after renal mass reduction
and increased progressively to 3.167 ± 0.410 g/day and 2.467 ±
0.758 g/day urinary protein excretion at six-month time point
in the RMR and RMR + CAA groups, respectively, whereas
it did not change in the SO groups. Also, from three-month
time point creatinine clearance values were significantly
lower in the RMR groups compared with the SO groups and
reached 0.73 ± 0.10 and 0.92 ± 0.11ml/min/Kg body weight in
the RMR and RMR +CAA groups, respectively, at six-month
time point. As shown in Table 2, no significant differences
were found between the RMR groups in any of the param-
eters of renal function. However, at six-month time point
the animals belonging to the RMR + CAA group present
lower values of urinary flow, phosphorus, potassium, BUN,
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Figure 2: Kidney catalase (a) and glutathione reductase (b) activities, GSH/GSSH ratio (c), malondialdehyde (d), and lipid hydroperoxides
(e) levels in experimental groups. a,b,cDifferences between groups with the same letter are not statistically significant (𝑝 < 0.05).
creatinine, and proteinuria and higher values of urine specific
gravity and creatinine clearance than those of theRMRgroup,
but the differences were not statistically significant.
3.5. Oxidative Stress. Our next step was to investigate the
effects of CAA administration on important cellular antiox-
idant defenses (Figure 2). It was observed that RMR was
accompanied by a reduction in CAT and GR activity and
a decrease in GSH/GSSG ratio. CAA administration sig-
nificantly increased CAT and GR activity and increased
GSH/GSSG ratio, but no significant differences between the
treated and nontreated groups were found in this ratio.
Regarding the oxidative damage to the biological compounds
in the renal tissue it is observed in Figure 2 that MDA and
BioMed Research International 7
lipid hydroperoxides levels, indicators of lipid peroxidation
stage, were increased in RMR groups compared with SO
groups; however these differences were not statistically sig-
nificant between RMR and RMR + CAA groups.
4. Discussion
CKD is a major health problem worldwide and because
oxidative stress plays an important role on its pathogenesis
[1, 4], compounds capable of attenuating this process should
attract particular interest for evaluation in treating CKD.
Therefore, considering that CAA can reduce oxidative stress
in human renal proximal tubular cells [17], in the present
work, we evaluated different oxidative stress parameters,
namely, MDA, lipid hydroperoxides, and GSH/GSSG ratio,
as well as the activities of the antioxidant enzymes CAT
and GR in homogenates from the kidney of rats subjected
to 5/6th nephrectomy, in the hope to contribute to new
therapeutic modalities for the treatment of CKD. We also
investigated if CAA attenuated the development of renal
failure by evaluating urine specific gravity, urinary flow,
phosphorus, potassium, BUN, creatinine, proteinuria, and
creatinine clearance. To our knowledge, this is the first study
evaluating the effect of chronic administration of CAA, a
selective inhibitor of membrane-bound Ha-Ras, on renal
function and oxidative stress in the kidney of rats with 5/6th
renal mass reduction.
Surgical renal mass reduction in rats is a widely studied
animal model of chronic renal failure that is close enough
to the pathophysiological characteristics of human CKD
[31]. This model is characterized by progressive renal failure,
proteinuria, and oxidative stress [19, 31–34]. So, we used this
model to assess the potential renoprotective effects of CAA.
Experimental data in animal models suggest beneficial
effects of antioxidant agents on renal outcomes in CKD
[35–40]. In fact, in this study we observed that long-term
CAA treatment attenuates oxidative stress in rats with CKD.
However, the mortality was higher in animals treated with
CAA.
It was observed that although the mortality was higher in
the RMR group treated with CAA, the rats died only from
the fifth month after RMR. The employed dose of CAA was
0.23 𝜇g/Kg, according to Sabbatini et al. [41]. These authors
pretreated the rats with CAA only one time, while we treated
our animals with the same dose three times a week for six
months. We did not observe adverse effects after the admin-
istration of such doses of CAA to rats. Therefore, probably
chronic administration of CAA (0.23 𝜇g/Kg) may have some
toxicity in rats with enhanced oxidative stress and renal
failure, while in healthy animals with a well-balanced redox
state and renal function administration of CAA is innocuous.
To the best of our knowledge, the toxicological properties
of this compound have not been fully investigated. We have
measured the renal content of glutathione S-transferase, a
phase II detoxification enzyme that plays an important role
in elimination of toxic compounds. However, we did not find
significant differences between CAA-treated and not treated
RMR animals.
Perturbations in cellular oxidant handling influence
downstream cellular signaling and, in the kidney, promote
renal cell apoptosis and senescence, decreased regenerative
ability of cells, and fibrosis. These factors have a stochastic
deleterious effect on kidney function [2]. So, typical clinical
characteristics of CKD include decreased glomerular filtra-
tion rate, proteinuria, and anemia. In this study, progression
of renal failure was followed over six months and, as in other
studies [19, 42], RMR animals developed renal failure, as
assessed by decreased creatinine clearance (an indirect mea-
sure of glomerular filtration rate), increased serum creatinine
and blood urea nitrogen (BUN), and proteinuria. In general,
in animals treated with CAA, all the above alterations were
slightly improved, but not statistically significant differences
were found between treated and untreated RMR groups.
Oxidative stress in CKD is caused by a combination of
excessive ROS production and antioxidant depletion. MDA
is an end-product generated by lipid peroxidation and has
been used to demonstrate increased oxidative stress during
CKD [43, 44]. Several studies demonstrated that renal MDA
contents were increased in rats with CKD [32, 42, 45, 46].
Another indicator of lipid peroxidation is the lipid hydroper-
oxides, well known intermediates of peroxidative reactions
[5, 47]. In this study, we found higher oxidative stress
levels, as indicated by renal MDA and lipid hydroperoxides
concentrations, in the RMR groups compared to the levels
observed in SO groups. Although significant differences were
not found between RMR groups, MDA and lipid hydroper-
oxides concentrations were slightly lower in CAA-treated
group. In addition, the GSH/GSSG ratio was lower in the
RMR group compared with RMR + CAA group. Kim and
Vaziri [48] also observed that GSH/GSSG ratio wasmarkedly
diminished in rats subjected to 5/6 nephrectomy. Glutathione
is a tripeptidic thiol found in the inside of all animal cells
and likely is the most important cellular antioxidant. This
tripeptide exists predominantly in its reduced form, GSH.
GSH is utilized for a broad range of functions, including
peroxide clearance and xenobiotic metabolism. Utilization
of GSH by antioxidant enzymes generates the oxidized,
dimer form of glutathione: GSSG [43].Thus, determining the
ratio of GSH/GSSG is considered a reliable estimate of the
degree of cellular oxidative stress. An increase in GSH/GSSG
is indicative of augmented antioxidant capacity, whereas a
decrease is suggestive of oxidative stress and diminished
antioxidant defenses. So, our findings point to increased
ROS-induced lipid peroxidation and glutathione oxidation in
the RMR groups. However, the degree of these alterations was
slightly diminished in animals treated with CAA.
Redox systems including antioxidant enzymes and
antioxidant agents provide protection against ROS-induced
tissue injury. Glutathione reductase and catalase are among
the main enzymatic antioxidants [5, 44]. In this study the
administration of CAA was associated to a significantly
increased activity of the antioxidant enzymes catalase and
glutathione reductase.
Oxidative stress plays an important role in renal lesion
induced by 5/6 nephrectomymodel [32, 33, 49] and treatment
with antioxidants prevents the progression of kidney disease
in this model [35, 38–40, 49–52] and preserves the function
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and structure of the stenotic kidney [53–55]. Significant
upregulation of NAD(P)H oxidase, a main source of ROS
in the kidney, has been demonstrated in this model [36,
56]. It was established that expression of activated Ha-Ras
can increase intracellular levels of ROS via upregulation
of the plasma membrane NAD(P)H oxidase [10, 14]. CAA
selectively blocks Ha-Ras farnesylation. So, this can explain
why the administration of CAA in RMR animals attenuated
RMR-induced stress oxidative.
5. Conclusions
In the present study, RMR increased the MDA and lipid
hydroperoxides levels, decreased renal endogenous antiox-
idant enzymes, and deteriorated the renal function. Long-
term CAA administration (0.23 𝜇g/Kg three times a week,
for six months) is associated with a slight reduction of renal
MDA and lipid hydroperoxides levels, significant increase in
the levels of antioxidant enzymes, and a slight improvement
of some parameters of renal function. These data suggest
that CAA could attenuate 5/6 RMR-induced oxidative stress
mainly by preventing the decrease of antioxidant enzymes.
However, potential clinical benefits of CAA therapy require
further studies. Although no adverse effect was observed
in CAA-treated SO animals, the mortality was higher in
RMR animals treated with CAA.Thus, studies on the clinical
toxicity and safety of CAA are necessary.
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